If you’re starting semaglutide, or thinking about it, the side effects are probably your biggest question. Most people get something, usually mild and usually in the stomach. Here’s what’s common, what’s rare but serious, and where the line sits between “ride it out at home” and “call your prescriber today.”
Educational information, not medical advice. Semaglutide (sold as Ozempic, Wegovy, and Rybelsus) is a prescription-only medication that must be started, adjusted, and stopped under the supervision of a licensed prescriber. Many peptides sold online are labeled “research use only” and are not FDA-approved for human use. Talk to a doctor or pharmacist before you start, change, or stop any dose. Don’t use this article to self-treat or to source unapproved substances.
The quick answer
The most common semaglutide side effects are gastrointestinal: nausea, constipation, diarrhea, vomiting, and reflux. They usually show up early, peak around dose increases, and fade as your body adjusts. Slow titration and a few diet tweaks blunt most of it. Serious problems (pancreatitis, gallbladder disease, a boxed thyroid-tumor warning) are uncommon but real, and a handful of people should never take it at all.
Lose weight
Gain muscles
Eat healthy
Explore new cuisinesWhat are the most common semaglutide side effects?
Semaglutide is a GLP-1 receptor agonist. It slows how fast your stomach empties and quiets appetite signals, which is exactly why it works for weight loss and why your gut complains at first. In the obesity trials, GI symptoms were by far the most frequent complaint.12
The usual lineup:
- Nausea — the most common, especially in the first weeks and right after a dose increase
- Constipation — slow gut motility is part of the drug’s job
- Diarrhea — sometimes alternating with constipation
- Vomiting — less common than nausea, but possible at higher doses
- Reflux, burping, bloating — that “food sits forever” feeling
- Fatigue and headache — often tied to eating less and dehydration
For most people these are mild to moderate and temporary. In the STEP and SURMOUNT programs, GI effects were the main reason a minority of participants stopped, but the large majority pushed through.13 If you want the broader picture of how this drug class behaves, our overview of GLP-1 medications for weight loss puts semaglutide in context.
How do you reduce the nausea and stomach problems?
Two levers do most of the work: how fast you go up in dose, and how you eat.
Titration. Semaglutide is started low and increased slowly on purpose, typically over months. Rushing the schedule is the fastest way to feel miserable. If a dose step is rough, prescribers often hold you at the current dose longer rather than climbing. Our guide to semaglutide dosage walks through the standard ramp.
Diet and habits that help:
- Eat smaller portions and stop at “satisfied,” not full
- Go easy on greasy, fried, and very rich meals — fat slows the stomach even more
- Sip water through the day; dehydration makes nausea and headaches worse
- Don’t lie down right after eating
- Bland, lower-fat foods (toast, rice, crackers, broth) on bad days
A GLP-1-friendly eating pattern is its own skill. We cover meal structure, protein, and fiber timing in the GLP-1 diet guide. Fiber and fluids together are also your main defense against constipation.
| Symptom | Manage at home | Call your prescriber |
|---|---|---|
| Mild nausea | Smaller, low-fat meals; ginger; fluids | Persistent vomiting, can’t keep fluids down |
| Constipation | Fiber, water, movement, gentle laxative if OK’d | No bowel movement for days, severe pain, bloating |
| Diarrhea | Fluids, electrolytes, bland foods | Signs of dehydration, blood, lasting >2 days |
| Reflux | Smaller meals, stay upright after eating | Severe or worsening, trouble swallowing |
| Fatigue/headache | Hydrate, don’t under-eat, check protein | Dizziness, fainting, confusion |
What are the rare but serious risks?
These are uncommon, but they’re the ones worth recognizing fast.
- Pancreatitis. Sudden, severe upper-abdominal pain that may radiate to your back, often with vomiting. Stop and seek medical care.
- Gallbladder problems. Rapid weight loss itself raises gallstone risk; signs include pain in the upper-right belly, fever, or yellowing of the skin or eyes.
- Boxed thyroid warning. In rodents, semaglutide caused thyroid C-cell tumors. Whether this translates to humans is unknown, but the FDA label carries a boxed warning. Watch for a neck lump, hoarseness, trouble swallowing, or shortness of breath.
- Kidney injury from dehydration, usually downstream of heavy vomiting or diarrhea.
- Low blood sugar, mainly if you also take insulin or a sulfonylurea.
- Severe allergic reaction — rare, but rash, swelling, or breathing trouble is an emergency.
A review of GLP-1 tolerability and risk lays out these signals and who’s most vulnerable.4 If you’re comparing options, tirzepatide’s side-effect profile is broadly similar, with its own dosing nuances.
Suggested read: Liraglutide vs Semaglutide: Daily vs Weekly GLP-1
Who should not take semaglutide?
Some histories are hard contraindications. Semaglutide is not recommended if you or a close family member has:
- Medullary thyroid carcinoma (MTC) — personal or family history
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
It also needs caution or avoidance with a history of pancreatitis, severe gastrointestinal disease (including gastroparesis), and during pregnancy or while trying to conceive.4 This is exactly why the drug is prescription-only: your prescriber screens for these before writing it. Be honest about your full and family medical history.
Does semaglutide cause muscle loss and “Ozempic face”?
Yes, and it’s worth taking seriously. When you lose weight fast on any approach, some of what you drop is lean mass, not just fat. With GLP-1 drugs, studies estimate that a meaningful share of total weight lost can come from lean tissue if you do nothing to protect it.56
That same fat loss in the face is what people call “Ozempic face” — hollowing and sagging that comes from losing the fat pads under the skin, plus loose skin after a big drop. It’s cosmetic, not dangerous, but it bothers people.
How to protect muscle (and your face fares better too):
- Eat enough protein. A higher protein intake during weight loss helps preserve lean mass. See our notes on how much protein per day.
- Do resistance training two to three times a week — this is the single biggest lever.
- Don’t crash your calories. Semaglutide already curbs appetite; the goal isn’t to eat as little as possible.
Researchers are even testing drugs that block muscle-wasting pathways to pair with GLP-1 therapy, a sign of how real this concern is.5 Hair shedding can also happen with rapid loss; that’s covered in weight loss and hair loss, and it’s usually temporary.
Suggested read: Microdosing GLP-1: What It Means and the Risks
What about the benefits side of the ledger?
Side effects only matter relative to what you gain. Semaglutide isn’t only about the scale.
- Weight loss: in STEP 1, adults on semaglutide 2.4 mg lost about 14.9% of body weight over 68 weeks, versus roughly 2.4% on placebo.1
- Cardiovascular protection: in the SELECT trial, people with obesity and existing heart disease but no diabetes had about a 20% lower risk of major cardiovascular events (heart attack, stroke, cardiovascular death).7
That heart benefit is a genuinely big deal and part of why prescribers weigh the GI nuisance as worth tolerating for many patients. The appetite suppression that drives the weight loss is the same mechanism behind the nausea — they’re two sides of one coin, and you can read more on how GLP-1 reduces hunger and appetite.
When should you actually call a doctor?
Manage the mild stuff at home. Reach out the same day for any of these:
- Severe or persistent abdominal pain (especially radiating to the back)
- Vomiting or diarrhea you can’t control, or signs of dehydration (dizziness, dark urine, no tears)
- A new lump in your neck, hoarseness, or trouble swallowing or breathing
- Yellowing of skin or eyes, or upper-right belly pain with fever
- Symptoms of low blood sugar if you’re on other diabetes meds
- Any rash, swelling, or breathing difficulty (treat as an emergency)
Never adjust or stop your dose on your own to chase relief — talk to your prescriber, who can slow the titration, pause, or switch you.
Suggested read: Tirzepatide Dosage Chart: Titration & Units Guide
Bottom line
Semaglutide side effects are mostly predictable: gut upset that’s worst early and around dose bumps, manageable with slow titration, smaller low-fat meals, and steady fluids. The serious risks (pancreatitis, gallbladder disease, the boxed thyroid warning) are uncommon, and a few histories like MTC or MEN2 rule the drug out entirely. Protect your muscle with protein and resistance training, weigh the real cardiovascular upside, and keep your prescriber in the loop on every change. Is semaglutide safe? For most appropriately screened people under medical supervision, the evidence says the benefits outweigh the risks, but that’s a call to make with your doctor, not on your own.
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PubMed ↩︎ ↩︎ ↩︎
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PubMed ↩︎
Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PubMed ↩︎
Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024;12:100127. PubMed ↩︎ ↩︎
Nunn E, et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Mol Metab. 2024;80:101880. PubMed ↩︎ ↩︎
Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26 Suppl 4:16-27. PubMed ↩︎
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed ↩︎
